A股異動 | 健友股份(603707.SH)逆勢漲4% 獲券商看好
格隆匯9月29日丨健友股份(603707.SH)衝高回落,盤中最高建35.76元創近五個月新高,現報35.05元,漲幅4%,最新總市值426.5億。浙商證券指,公司是受益於特有資源產業升級的肝素龍頭,基於公司在合規生產、工藝開發領域的優勢,收入結構調整期,業績增長持續性有望超預期。考慮到2022-2023年原料藥收入佔比明顯下降、製劑出口收入佔比明顯提升,估算公司整體估值仍有較大提升空間,將公司評級上調至“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.